Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Ribera

Showing results (301-310 of 310) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 310 results.
Leukemia|February 7, 2012
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemiaA Vilas-Zornoza, X Agirre, G Abizanda, et al.
Blood Cancer Journal|October 3, 2015
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|August 30, 2007
[Recommendations for diagnosis and treatment of aged hypertensives]J Macías, N R Robles, J Herrera, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patientsJ Bladé, J F San Miguel, M Fontanillas, et al.
British Journal of Haematology|July 27, 2001
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA groupM González, E Barragán, P Bolufer, et al.
Leukemia Research|April 11, 2022
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteriaA Triguero, B Xicoy, L Zamora, et al.
Journal of Hematology & Oncology|July 26, 2018
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemiaE Genescà, A Lazarenkov, M Morgades, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
Current Alzheimer Research|June 30, 2012
Progression of Alzheimer disease in Europe: data from the European ICTUS studyB Vellas, L Hausner, L Frölich, et al.
Pageof 31

Showing results (301-310 of 310) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 310 results.
Leukemia|February 7, 2012
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemiaA Vilas-Zornoza, X Agirre, G Abizanda, et al.
Blood Cancer Journal|October 3, 2015
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|August 30, 2007
[Recommendations for diagnosis and treatment of aged hypertensives]J Macías, N R Robles, J Herrera, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patientsJ Bladé, J F San Miguel, M Fontanillas, et al.
British Journal of Haematology|July 27, 2001
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA groupM González, E Barragán, P Bolufer, et al.
Leukemia Research|April 11, 2022
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteriaA Triguero, B Xicoy, L Zamora, et al.
Journal of Hematology & Oncology|July 26, 2018
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemiaE Genescà, A Lazarenkov, M Morgades, et al.
Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.
ESMO Open|March 10, 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusC Buske, M Dreyling, A Alvarez-Larrán, et al.
Current Alzheimer Research|June 30, 2012
Progression of Alzheimer disease in Europe: data from the European ICTUS studyB Vellas, L Hausner, L Frölich, et al.
Pageof 31